BioPharmSignal logoBioPharmSignal

Biotech News

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Lixte Biotechnology Holdings (LIXT)Lixte Biotechnology HoldingsClinical readout

LIXT (LIXT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lixt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

GNLXGenelux2026-06-30 12:00 EST

Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

ERASErasca2026-07-13 20:01 EST

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

GSKGSK plc2026-07-28 11:00 EST

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

View all latest news

Lixte Biotechnology Holdings

PP2A Inhibition in Cancer LIXTE Biotechnology develops cancer therapies based on inhibition of protein phosphatase 2A. Its lead molecule is intended to sensitize tumors to chemotherapy and immunotherapy rather than function solely as a stand-alone cytotoxic drug. LB-100 LB-100 is a first-in-class clinical PP2A inhibitor that has shown...

Recent company news

LIXTLixte Biotechnology Holdings2026-08-19 12:30 EST

NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System

LIXTLixte Biotechnology Holdings2026-08-14 12:35 EST

NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE

LIXTLixte Biotechnology Holdings2026-07-31 12:30 EST

NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange

LIXTLixte Biotechnology Holdings2026-07-29 12:30 EST

NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative

LIXTLixte Biotechnology Holdings2026-07-15 12:30 EST

NOMAD Power Solutions Strengthens Subsidiary Executive Leadership

Stock data

Close
7.21 USD
Market cap
87.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States